I-Oseltamivir phosphate lichiza le-antiviral elisetyenziswa kunyango lwe-acute uncomplicated usulelo lomkhuhlane kubantu abadala, abafikisayo kunye nabantwana (≥2 iiveki ubudala). I-Oselavir® iya kufumaneka e-China kwifom ye-dosage - 12.5ml: i-75mg powder yokumiswa komlomo.
I-WHO iqikelela ukuba umkhuhlane wexesha lonyaka unokukhokelela ekufeni kwabantu abangama-290,000-650,000 nyaka ngamnye ngenxa yezifo zokuphefumla kuphela. Uqikelelo aluthatheli ngqalelo ukufa okuvela kwezinye izifo ezifana nesifo sentliziyo, esinokuba sinxulumene nomkhuhlane1.
UDkt. Vamsi Krishna Bandi, uMlawuli oLawulayo, i-Hetero Group of Companies uthe, "Siyavuya ukuba i-Hetero ngokubambisana ne-Shenzhen Beimei Pharmaceuticals, e-China, ifumene imvume ye-Oselavir® (Oseltamivir) e-China. Le yimveliso yokuqala egqityiweyo yokuvunywa kwe-Hetero e-China, kwaye sizimisele ukuzisa iimveliso ezininzi e-China kungekudala. "
UNksz Guangmei Wu, uMongameli kunye ne-CEO ye-Shenzhen Beimei Pharmaceuticals uthe, "Ngokuthembana kunye nenkxaso phakathi kweqela le-Beimei ne-Hetero, i-Oselavir® yasungulwa e-China njengemveliso yokuqala yase-China evunyiweyo ye-Oseltamivir kwifomu yedosi yabantwana. Ndivakalisa umbulelo kwiqela le-Hetero ngomsebenzi wabo onzima kunye nomzamo kuyo yonke inkqubo yokuphuhliswa kwemveliso, isicelo sokubhalisa kunye nokuqaliswa kokulungiselela i-Oselavir®. Sijonge phambili ekujongeni iimveliso ezininzi ngeHetero kukhathalelo lwempilo yabantwana kwihlabathi kwixesha elizayo. ”